{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:42Z","timestamp":1786118922289,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Observational studies have shown that kidney transplant (KT) recipients who are cytomegalovirus (CMV)-seropositive (R+) but lack effective CMV-specific cell-mediated immunity (CMV-CMI) are at increased risk of CMV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>In this quasi-experimental study, an immune-guided prevention strategy based on early CMV-CMI assessment (1\u20132 posttransplant weeks) was evaluated in intermediate-risk KT recipients (R+ without lymphocyte-depleting induction). CMV-CMI was measured using the QuantiFERON assay (QTF-CMV). Recipients with nonreactive QTF-CMV received antiviral prophylaxis until either CMV-CMI reconstitution or month 6, while those with reactive QTF-CMV were managed with preemptive therapy. The primary outcome was the proportion of patients who developed CMV infection during the first posttransplant year. Secondary outcomes included CMV disease, CMV DNAemia requiring preemptive therapy, rejection, vascular events, and all-cause mortality. Outcomes were compared with a prospective preintervention cohort managed by standard-of-care preemptive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      We included 91 and 100 patients in the preintervention and intervention groups, with similar baseline characteristics. One-year incidence of CMV infection was similar between both groups (48.4% versus 50.0%; odds ratio [OR], 1.07; 95% confidence interval [CI], 0.61-1.89;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.820). One-year incidence of CMV disease (secondary outcome) was lower in the intervention group (9.9% versus 3.0%; OR, 0.28; 95% CI, 0.07-1.08;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.064), as confirmed in the per-protocol analysis (9.9% versus 2.2%; OR, 0.20; 95% CI, 0.04-0.97;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Although the tested QTF-CMV-based immune-guided strategy did not result in a reduction in the overall occurrence of CMV infection in intermediate-risk KT recipients, the lower incidence of CMV disease observed merits further research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005694","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:06:03Z","timestamp":1776787563000},"page":"e1265-e1275","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of an Immune-guided Prevention Strategy Against CMV Among Intermediate-risk Kidney Transplant Recipients: A Quasi-experimental Study"],"prefix":"10.1097","volume":"110","author":[{"given":"Jos\u00e9 Mar\u00eda","family":"Caso","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."},{"name":"Department of Nephrology, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Polanco","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Redondo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ruiz-Merlo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"San-Juan","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Allende","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."},{"name":"Department of Immunology, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Paz-Artal","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."},{"name":"Department of Immunology, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado","family":"Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."},{"name":"Department of Nephrology, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"L\u00f3pez-Medrano","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rodr\u00edguez-Goncer","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre,\u201d Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Madrid, Spain."},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain."},{"name":"Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"R1-20260521","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease.","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"e00043-19","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation.","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"100875","DOI":"10.1016\/j.trre.2024.100875","article-title":"Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update.","volume":"38","author":"Ruiz-Arabi","year":"2024","journal-title":"Transplant Rev"},{"key":"R5-20260521","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.coi.2022.102185","article-title":"T cell immunity to cytomegalovirus infection.","volume":"77","author":"Zangger","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/TP.0000000000005218","article-title":"Immune monitoring assays: predicting cytomegalovirus and other infections in solid organ transplant recipients.","volume":"109","author":"Gardiner","year":"2025","journal-title":"Transplantation"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.3389\/ti.2023.11963","article-title":"Cytomegalovirus cell-mediated immunity: ready for routine use?","volume":"36","author":"Bestard","year":"2023","journal-title":"Transpl Int"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation.","volume":"13","author":"Cantisan","year":"2013","journal-title":"Am J Transplant"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/ajt.12256","article-title":"Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation.","volume":"13","author":"Bestard","year":"2013","journal-title":"Am J Transplant"},{"key":"R10-20260521","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.TP.0000438025.96334.eb","article-title":"Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.","volume":"97","author":"Lopez-Oliva","year":"2014","journal-title":"Transplantation"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"381.e1","DOI":"10.1016\/j.cmi.2018.05.010","article-title":"Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.","volume":"25","author":"Fernandez-Ruiz","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","article-title":"Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial.","volume":"71","author":"Jarque","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum.","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/tri.12586","article-title":"Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.","volume":"28","author":"Fernandez-Ruiz","year":"2015","journal-title":"Transpl Int"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation.","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial.","volume":"74","author":"Paez-Vega","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/cid\/ciad575","article-title":"Immune monitoring-guided versus fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients: a multicenter, randomized clinical trial.","volume":"78","author":"Manuel","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/TP.0000000000005173","article-title":"Cell-mediated immunity to guide primary prophylaxis for CMV infection in organ transplant recipients: a multicenter single-arm prospective study.","volume":"109","author":"Solera","year":"2025","journal-title":"Transplantation"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.healun.2022.05.004","article-title":"Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.","volume":"41","author":"Gardiner","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"e14437","DOI":"10.1111\/tid.14437","article-title":"Diagnostic performance of two different techniques to quantify CMV-specific cell-mediated immunity in intermediate-risk seropositive kidney transplant recipients.","volume":"28","author":"Fernandez-Ruiz","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"e28733","DOI":"10.1002\/jmv.28733","article-title":"Comparison of intracellular cytokine staining versus an ELISA-based assay to assess CMV-specific cell-mediated immunity in high-risk kidney transplant recipients.","volume":"95","author":"Fernandez-Ruiz","year":"2023","journal-title":"J Med Virol"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/microorganisms13030589","article-title":"Quantifying gamma-interferon from CMV-specific CD8+ T cells defines protection against clinically significant CMV infection in solid organ transplant recipients: the Quanti-CMV score.","volume":"13","author":"Ruiz-Arabi","year":"2025","journal-title":"Microorganisms"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/tid.12417","article-title":"Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+\/R- solid organ transplant recipients.","volume":"17","author":"San-Juan","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jiaa503","article-title":"Pretransplant CMV-specific T-cell immunity but not dose of antithymocyte globulin is associated with recovery of specific immunity after kidney transplantation.","volume":"223","author":"Paez-Vega","year":"2021","journal-title":"J Infect Dis"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation.","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"211 e211","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis.","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R29-20260521","article-title":"Letermovir prophylaxis does not hinder immune reconstitution while reshaping viral infection landscape in children.","author":"Spadea","journal-title":"Transplant Cell Ther"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial.","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"e14227","DOI":"10.1111\/tid.14227","article-title":"Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1017\/ice.2016.117","article-title":"Research methods in healthcare epidemiology and antimicrobial stewardship-quasi-experimental designs.","volume":"37","author":"Schweizer","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ajt.13012","article-title":"Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates.","volume":"15","author":"Cantisan","year":"2015","journal-title":"Am J Transplant"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14787210.2020.1733976","article-title":"Predictive tools to determine risk of infection in kidney transplant recipients.","volume":"18","author":"Fernandez-Ruiz","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/TP.0000000000004870","article-title":"QuantiFERON-CMV as a predictor of CMV events during preemptive therapy in CMV-seropositive kidney transplant recipients.","volume":"108","author":"Reusing","year":"2024","journal-title":"Transplantation"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/13696998.2022.2046388","article-title":"Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.","volume":"25","author":"Cheng","year":"2022","journal-title":"J Med Econ"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:08:33Z","timestamp":1786036113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005694","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}